RLV.V - Relevium Technologies Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.0750
0.0000 (0.00%)
At close: 3:54PM EDT
Stock chart is not supported by your current browser
Previous Close0.0750
Open0.0750
Bid0.0700 x 0
Ask0.0750 x 0
Day's Range0.0700 - 0.0750
52 Week Range0.0500 - 0.1900
Volume147,000
Avg. Volume728,247
Market Cap10.563M
Beta (3Y Monthly)0.80
PE Ratio (TTM)N/A
EPS (TTM)-0.0350
Earnings DateFeb 27, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire14 days ago

    Relevium Signs Exclusivity Agreement With SOSCannabis.com for Reimbursement for Pediatric Patients

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today it has executed an exclusivity agreement to partner with SOS cannabis Inc. (“SOSCannabis”), which will provide pediatric customers with the ability to obtain free legal representation to seek reimbursement for the costs of medical cannabinoid therapy from different government agencies for the treatment of medical conditions for pediatric patients. The partnership agreement will provide Relevium’s pediatric customers with access to an experienced legal and case management team, who will prepare the case file and seek retroactive and prospective reimbursement for parents of pediatric patients at no cost.

  • GlobeNewswire21 days ago

    Relevium’s CEO Issues Letter of Clarification to Shareholders  

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today a letter from Aurelio Useche, CEO to shareholders to clarify misconceptions and rumours in the market about a compliance news release disseminated on July 1, 2019 by the Company pursuant to a request from the OTC Markets Group. The Management of Relevium or any publicly traded company has the responsibility to dispel unfounded rumours, misinformation or false statements which result in unusual market activity. As CEO, director and shareholder of Relevium Technologies Inc. I feel it necessary to issue this letter and issue a clear and direct clarification regarding inaccurate and misleading statements being made by independent blog and referral traffic investor website equity.guru and Mr. Chris Parry.

  • GlobeNewswire23 days ago

    Relevium Issues Statement Regarding Recent Promotional Activity

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today that it has been made aware of and requested by the OTC Markets Group, Inc. to comment on recent promotional activity concerning its common shares traded on the OTCQB market. On June 27th, 2019, the OTC Markets Group sent the Company copies of three newsletters sent on June 25 and June 26, 2019 by SmallCapFirm, a third-party marketing and awareness firm utilized by StockWireNews, LLC (“StockWireNews”), which in turn was utilized by one of the Company’s marketing firms, Shore Thing Media, LLC (“Shore Thing”).

  • Baystreet28 days ago

    Stocks in play: Relevium Technologies Inc.

    Is positioning itself as an important player in the Colombian medical cannabis market by cementing medical ...

  • GlobeNewswire28 days ago

    Relevium’s Biocannabix Positions Itself as an Important Player in Colombia as it Pursues Endo-Medical Cannabis Strategy for Latin America

    Relevium Technologies Inc. a Health and Wellness portfolio company listed on TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX” (the “Company” or “Relevium”) announced today it is positioning itself as an important player in the Colombian medical cannabis market  by cementing medical and research relationships in the country in order to establish clinical validation programs for its Endo Nutraceutical Supplements (ENS) and Oral Nutritional Supplements. On June 13th, 2019, the Company announced a binding LOI to acquire LifeLine Pharma SAS, a binding agreement to acquire the shares of Lifeline Pharma SAS, a Cali based cultivation and extraction business in the burgeoning agro-pharma market in Colombia.

  • GlobeNewswirelast month

    Relevium to Hold Investor Call to Discuss LATAM Strategy June 28, 2019 at 1:00pm EST

    Relevium Technologies Inc. a Health and Wellness portfolio company listed on TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX” (the “Company” or “Relevium”), is pleased to announce it will be holding a shareholder and investor conference call to discuss its Latin American (LATAM) strategy and the upside potential of its recently announced acquisition in Colombia. It is estimated that Colombia is positioned to supply about 44% of the World’s market for medical cannabis and the acquisition of Lifeline Pharma SAS  (“LifeLine”) in Colombia is set to allow Biocannabix Health Corporation to target two important sources of revenues: (1) EU GMP pharma-grade extracts for export and (2) endo-nutraceutical (ENS) and oral nutritional supplements (ONS) for in-country distribution.

  • CNW Grouplast month

    IIROC Trading Resumption - RLV

    VANCOUVER , June 13, 2019 /CNW/ - Trading resumes in: Company: Relevium Technologies Inc. TSX-Venture Symbol: RLV (All Issues) Resumption (ET): 11:00 AM IIROC can make a decision to impose a temporary ...

  • GlobeNewswirelast month

    Relevium Takes Major Step in Latam to Acquire Lifeline Pharma in Cali, Colombia

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that Biocannabix Health Corporation (“Biocannabix”), a wholly-owned subsidiary of Relevium has executed on June 12, 2019 a binding agreement to acquire the shares of Lifeline Pharma SAS, a Cali based cultivation and extraction business in the burgeoning agro pharma market in Colombia. Multi-stage project with (1) an initial 5 hectares that includes the local offices, a laboratory, a fully enclosed greenhouse for tissue culture and micropropagation and an initial cultivation of over 200,000 square feet in open air green houses, (2) an option to expand to an additional 20 hectares or 2.2 million square feet of open air greenhouse cultivation and (3) the possibility to expand to another additional 60 hectares or 6.5 million square feet of cultivation.

  • CNW Grouplast month

    IIROC Trading Halt - RLV

    VANCOUVER , June 13, 2019 /CNW/ - The following issues have been halted by IIROC: Company: Relevium Technologies Inc. TSX-Venture Symbol: RLV (All issues) Reason:  At the Request of the Company Pending ...

  • GlobeNewswirelast month

    Relevium Closes Private Placement Financing

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that it has closed a non-brokered private placement financing for a total of 15,350,000 units (the "Units") at $0.08 per Unit, for total gross proceeds of $1,228,000. Each Unit consists of one common share of Relevium and one common share purchase warrant entitling the holder to purchase one additional common share at $0.12 per share for a period of one year from the date of the issue. Relevium has the right to accelerate the expiry date of the Warrants if, at any time, the average closing price of Relevium’s common shares is equal to or greater than $0.15 for 10 consecutive trading days.

  • GlobeNewswire2 months ago

    Relevium’s Biocannabix Executes LOI to Acquire 30% Interest in Weedsense, a Late Stage Applicant for Standard Processing and Medical Sales License

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce its wholly owned subsidiary Biocannabix Health Corporation (“Biocannabix”) has executed an LOI to acquire 30% of Weedsense Inc., a late stage applicant for standard processing and medical sales license. Weedsense Inc. (“Weedsense”) is building a wholesale and distribution business in Montreal, Québec.

  • GlobeNewswire2 months ago

    Relevium Provides Corporate Update on Its Medical Cannabis Strategy

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to provide a corporate update on the Company’s positioning and strategy regarding medical cannabis and CBD Nutraceuticals. The Food and Drug Administration (the “FDA”), held a key public hearing last Friday regarding its role in regulating cannabis-derived products such as CBD as nutritional supplements. The FDA’s position is that although hemp is no longer an illegal substance under federal law, the FDA continues to regulate cannabis products under the Food, Drug, and Cosmetic Act (“FD&C Act”) and Section 351 of the Public Health Service Act.

  • GlobeNewswire2 months ago

    Relevium Launches New Line of High-End Omega Fish Oils Targeting Inflammation, Heart and Vision    

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that its OTC business has launched a new line of omega fish oils based formulations targeting inflammation, heart and vision care. The Company has launched an initial two omega formulated products to support heart health and vision care: CardiaProtm and VisionProtm, leading the way to a complete line of scientifically formulated products targeting inflammation. Inflammation, which is a process by which the body's natural immune response seeks to protect us from infection with foreign organisms, such as bacteria and viruses.

  • GlobeNewswire2 months ago

    Relevium Announces Private Share Purchase by CEO

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today that Mr. Aurelio Useche, Chief Executive Officer, has agreed to purchase a total of 4,213,713 common shares of Relevium, representing approximately 3% of Relevium’s total shares outstanding, from Mr. Albertus Engelbrecht in a private transaction. Relevium is a publicly-traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operations of brands and businesses in the Health and Wellness markets and medical cannabis.

  • GlobeNewswire2 months ago

    Relevium Announces Reprice of the 2016 and 2017 Series Warrants

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced the re-pricing 12,398,500 warrants series 2017 with an original exercise price of $0.15 and expiring June 16, 2019 and 3,258,000 warrants of series 2016 with an original exercise price of $0.15 and expiring August 16, 2019. The series 2016 and 2017 have been repriced to $0.10 and the new exercise price is only valid for a period of 29 days starting today and expiring June 15, 2019. The warrant re-price is subject to final approval by the TSX Venture Exchange.

  • GlobeNewswire5 months ago

    Relevium Reports Second Quarter Revenue Bounce Back for Fiscal 2019  

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to report second quarter results for fiscal 2019. During the second quarter ended December 2018, the Company’s revenue bounced back to $1,006,501 as compared to $968,474 in the second quarter of fiscal 2018. The Company also reported quarter-over-quarter increase in revenues from $985,051 reported for the first quarter of fiscal 2019.

  • GlobeNewswire5 months ago

    Walmart’s Influence in the Healthcare Sector; Spreading Health and Wealth as Vendors Capitalize on Spending

    Investorideas.com, a leading investor news resource covering technology and healthcare stocks releases a snapshot looking at increased quarterly sales for the sector thanks, in no small part, to Walmart. CNBC has reported on how Walmart is looking for ways to reduce health-care costs for its customers, and its employees. It’s goal to take a leading role in healthcare is now spreading and is having an impact on the sector overall.

  • GlobeNewswire5 months ago

    Relevium Announces DTC Eligibility for the US Market

    Relevium Technologies Inc. (TSX.V: “RLV”,  OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to announce it has secured eligibility by The Depository Trust Company (DTC) for its shares on the OTC. DTC is a subsidiary of the Depository Trust & Clearing Corp. that manages the electronic clearing and settlement of publicly traded companies in the United States. DTC eligibility will simplify the process of trading and is expected to enhance liquidity and overall visibility in the US OTC capital markets, where the Company trades under the symbol "RLLVF".

  • GlobeNewswire5 months ago

    Relevium Launches the Push and Pull System™, Targeting a New Revenue Stream in the Burgeoning Cosmeceutical Market

    Relevium Technologies Inc. (TSX.V: “RLV”,  OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the new launch of the Push and Pull System™, an innovation in delivering a comprehensive solution for skin care, designed specifically for today’s active women. The Push & Pull System™ by Bioganix® is the first ever comprehensive natural anti-aging system for complete skin care that combines Collagen Protein supplements (PUSH) and naturally sourced Aloe Vera skin anti-aging cream (PULL). This new launch is targeting a brand-new revenue stream in the burgeoning cosmeceutical market, which is the fastest growing segment of the health and wellness Market.